Tradestie Institutional Equity Comparison Engine
FOLD vs AKRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FOLD Overall Edge
FOLD Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Amicus Therapeutics, Inc (FOLD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, FOLD trades at 17.7x Forward P/E with 8.6% operating margin (+23.7% YoY revenue) versus AKRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, FOLD sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
FOLD
FOLD 17.7x vs AKRO N/M Fwd P/E
Growth & Margin Winner
FOLD
Op Margin 8.6% vs 0.0% ยท YoY +23.7% vs +0.0%
Momentum & Technical Winner
FOLD
1Y +104.1% vs +76.8% ยท 52W Pos 100% vs 90%
Options & Structure Winner
FOLD
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (30th %ile IV)
FOLD
NASDAQ
Amicus Therapeutics, Inc
Pharmaceutical Preparations
$14.49
+0.21% 1D
Market Cap
$4.5B
1M Return
+0.42%
1Y Return
+104.08%
Forward P/E
17.7x
Unified AI Score
59.4 / 100
HOLD
Tech 40.0
Fund 52.0
Flow 71.0
Mom 46.0
AKRO
NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap
$4.5B
1M Return
+1.37%
1Y Return
+76.75%
Forward P/E
N/M
Unified AI Score
60.0 / 100
BUY
Tech 55.0
Fund 52.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
FOLD +104.08%
AKRO +76.75%
Spread: +0.76 pp (FOLD Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
FOLD TTM Op. Margin: 8.6%
AKRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FOLD vs AKRO. Trailing 12-month operating profitability (FOLD 8.6% vs AKRO 0.0%) and valuation multiples (FOLD 17.7x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FOLD | AKRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.5B | $4.5B | Larger Scale | FOLD |
| Trailing P/E Ratio Valuation | 30.5x | N/M | Lower Multiple | FOLD |
| Forward P/E Ratio Valuation | 17.7x | N/M | Lower Multiple | FOLD |
| Revenue Growth (YoY) Growth | +23.7% | +0.0% | Higher Growth | FOLD |
| Operating Margin (TTM) Profitability | 8.6% | 0.0% | Higher Margin | FOLD |
| Net Profit Margin Profitability | -4.3% | 0.0% | Higher Margin | AKRO |
| Return on Equity (ROE) Capital Efficiency | -11.6% | -34.5% | Higher ROE | FOLD |
| 52-Week Range Position Momentum | 100% ($6โ$14) | 90% ($21โ$58) | Stronger Trend | FOLD |
| Beta / 30D Volatility Risk Regime | 0.27ฮฒ ยท 2% Vol | 0.90ฮฒ ยท 2% Vol | Lower Realized Risk | FOLD |
| Unified Institutional Score Composite Signal | 59.4 / 100 (HOLD) | 60.0 / 100 (BUY) | Higher Composite | AKRO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full FOLD vs AKRO Buy Guide
FOLD
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
AKRO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
30th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither FOLD nor AKRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.